CD8A and neoplasm: Blaszczak et al. [31] and McCaw et al. [32] have also verified that HDACis can upregulate tumor antigen expression, increase the number and cytotoxicity of NK and CD8+ cells to enhance cellular immunity, and thus increase the antitumor effects in vivo and in vitro, suggesting that there will be a synergistic effect if they are combined in antitumor therapy.